A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia

Journal of Immunotherapy

Volumn 31, Issue 8, 2008, Pages 723-730

  Kronenberger, Konrad ^a   Nöner, Elfriede ^a   Frankenberger, Bernhard ^a   Wahl, Ulrich ^b   Dreyling, Martin ^c   Hallek, Michael ^d   Mocikat, Ralph ^a,e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e Institut für Molekulare Immunologie   (Germany)

Author keywords

Dendritic cell; Immunotherapy; Trioma; Tumorassociated antigens

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; PROTEIN BCL 2; PROTEIN MDM2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV5; TRIOMA VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIGEN; DNA BINDING PROTEIN; ETV5 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; ACTIVE IMMUNIZATION; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TRANSPLANTATION;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIGENS; B-LYMPHOCYTES; CANCER VACCINES; DENDRITIC CELLS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS;

EID: 59849093180     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318183af26     Document Type: Article

References (31)

1. Coulie PG. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today. 1997;3:261-268.
2. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302.
3. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-1057.
4. Freud M, HeuXer P. Non-Hodgkin-lymphome niederer malignität. In: Seeber S, Schütte J, eds. Therapiekonzepte Onkologie. Berlin: Springer-Verlag;1996:189-268.
5. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000;4:5-21.
6. Hanada M, Delia D, Aiello A, et al. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820-1828.
7. Aguilar-Santelises M, Rottenberg ME, Lewin N, et al. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69:114-119.
8. Pettitt AR, Sherington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
9. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994;84:3158-3165.
10. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 2002;99:4554-4561.
11. Selmayr M, Strehl J, Kremer J-P, et al. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther. 1999;6:778-784.
12. Kronenberger K, Dieckmann A, Selmayr M, et al. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. Blood. 2002;99:1327-1331.
13. Mocikat R, Selmayr M, Thierfelder S, et al. Trioma-based vaccination against B cell lymphoma confers long-lasting tumor immunity. Cancer Res. 1997;57:2346-2349.
14. Strehl J, Selmayr M, Kremer J-P, et al. Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Int J Cancer. 1999;83:113-120.
15. Allgeier T, Garhammer S, NöXner E, et al. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Cancer Lett. 2007;245:275-283.
16. Adam C, Mysliwietz J, Mocikat R. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J Translat Med. 2007;5:16.
17. Wahl U, Nößner E, Kronenberger K, et al. Vaccination against B-cell chronic-lymphocytic leukemia with trioma cells: preclinical evaluation. Clin Cancer Res. 2003;9:4240-4246.
18. Zobywalski A, Javorovic M, Frankenberger B, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007;5:18.
19. Moosmann A, Khan N, Cobbold M, et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood. 2002;100:1755-1764.
20. Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells. Cancer Res. 2002;62:2347-2352.
21. Egeter O, Mocikat R, Ghoreschi K, et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res. 2000;60:1515-1520.
22. Kokhaei P, Palma M, Hannson L, et al. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol. 2007;35:297-304.
23. Rosenbauer F, Owens BM, Yu L, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet. 2006;38:27-37.
24. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4552-4557.
25. Bulrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24-27.
26. Counter CM, Gupta J, Harley CB, et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315-2320.
27. Ely SA, Chadburn A, Dayton CM, et al. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452.
28. Mayr C, Kofler DM, Büning H, et al. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood. 2005;106:3223-3226.
29. + autologous T lymphocytes. Exp Hematol. 2006;34:44-53.
30. Rezvany M-R, Jeddi-Tehrani M, Österborg A, et al. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood. 1999;94:1063-1069.
31. Rezvany M-R, Jeddi-Tehrani M, Wigzell H, et al. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood. 2003;101:1063-1070.